NCT02511236

Brief Summary

The purpose of this study is to test the effects of a group smoking cessation program. The study will also examine individual differences in response to the intervention program.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
356

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Aug 2015

Longer than P75 for phase_4

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 24, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 29, 2015

Completed
3 days until next milestone

Study Start

First participant enrolled

August 1, 2015

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 23, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 23, 2019

Completed
1.7 years until next milestone

Results Posted

Study results publicly available

June 24, 2021

Completed
Last Updated

June 24, 2021

Status Verified

June 1, 2021

Enrollment Period

4.2 years

First QC Date

July 24, 2015

Results QC Date

June 1, 2021

Last Update Submit

June 1, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • The Number of Participants Reporting 7 Day Point Prevalence Abstinence

    Reported will be the number of participants reporting 7 day point prevalence of smoking abstinence

    12-months

  • Change in Perceived Stress Scores

    The Perceived Stress Scale (PSS) is a 10-item questionnaire with scores ranging from 0-40 with higher scores indicated greater stress.

    Baseline, 4 weeks

  • Change in Depressive Symptoms Scores

    Depressive scores based on Center for Epidemiologic Studies Depression Scale (CESD). CESD has a total score ranging from 0-60 with a higher score indicating greater depressive symptoms.

    Baseline, 4 weeks

Study Arms (2)

Group Cognitive Behavioral Therapy

EXPERIMENTAL

Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) \[21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)\].

Behavioral: Group Cognitive Behavioral TherapyDrug: Transdermal Nicotine Patch

General Health Education

ACTIVE COMPARATOR

Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) \[21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)\].

Behavioral: General Health EducationDrug: Transdermal Nicotine Patch

Interventions

The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.

Group Cognitive Behavioral Therapy

The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).

General Health Education

Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.

Also known as: Nicotine Patch
General Health EducationGroup Cognitive Behavioral Therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Self-identify as African American/Black, Hispanic (any race), or White non-Hispanic
  • Smoke at least 5 cigarettes/day or carbon monoxide (CO) reading of at least 8 ppm
  • be over age 18
  • speak/read English and/or Spanish

You may not qualify if:

  • Contraindications for transdermal nicotine patch therapy (TNP)
  • Cognitive or mental health impairment that inhibits group treatment
  • Currently being treated for smoking cessation, alcoholism, or illicit drug use
  • Unable to attend sessions
  • Indications that participant is not appropriate for the study (e.g., aggressive, intoxicated, disruptive, visibly ill)
  • Does not self-identify as African American, Hispanic, or White (non-Hispanic)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Miami

Coral Gables, Florida, 33124, United States

Location

H Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States

Location

Related Publications (2)

  • Webb Hooper M, Lee DJ, Simmons VN, Brandon KO, Antoni MH, Asfar T, Koru-Sengul T, Brandon TH. Cognitive behavioral therapy versus general health education for smoking cessation: A randomized controlled trial among diverse treatment seekers. Psychol Addict Behav. 2024 Feb;38(1):124-133. doi: 10.1037/adb0000928. Epub 2023 May 4.

  • Webb Hooper M, Lee DJ, Simmons VN, Brandon KO, Antoni MH, Unrod M, Asfar T, Correa JB, Koru-Sengul T, Brandon TH. Reducing racial/ethnic tobacco cessation disparities via cognitive behavioral therapy: Design of a dualsite randomized controlled trial. Contemp Clin Trials. 2018 May;68:127-132. doi: 10.1016/j.cct.2018.03.017. Epub 2018 Apr 1.

MeSH Terms

Conditions

Smoking Cessation

Interventions

Tobacco Use Cessation Devices

Condition Hierarchy (Ancestors)

Health BehaviorBehavior

Intervention Hierarchy (Ancestors)

Therapeutics

Results Point of Contact

Title
David J. Lee
Organization
University of Miami Miller School of Medicine

Study Officials

  • David Lee, PhD

    University of Miami

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 24, 2015

First Posted

July 29, 2015

Study Start

August 1, 2015

Primary Completion

October 23, 2019

Study Completion

October 23, 2019

Last Updated

June 24, 2021

Results First Posted

June 24, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

Locations